An extension of your research team
Take as much or as little as the engagement needs — study design, fieldwork, moderation, analysis. You own the question and the client relationship; we bring the audiences and the delivery.
For consulting firms
Research capacity for the engagements that can’t wait.
Partner with our team at any point in the research cycle — quantitative, qualitative, focus groups and advisory boards — fielded on a verified network we own, on the timelines consulting work demands.
Start with one project150+
global consulting companies are our clients
1,200+
projects a year
300+
in-house recruiters and moderators
56+
countries, 12+ languages
What we run for you
Timelines consulting work demands
Feasibility typically back within a day; fieldwork launched in days. Built for two-week project sprints, not six-week cycles.
The audiences others decline
Rare disease, sub-specialty, payer, procurement and named-institution audiences — recruited by name, verified before the first answer.
Quality you can stand behind
Every respondent passes six verification layers. GrowthMix pairs online scale with live, moderated screen-share in the same study.
300+ in-house recruiters and moderators, dedicated QA, in-house programming and data processing, and an owned respondent community — not subcontractors. Accountability doesn’t survive a handoff, so we don’t hand off.
How it starts.
A relationship built one project at a time.
01
Brief us
The question, therapy area, audience, methodology and timeline — in a call or a paragraph.
02
Proposal, fast
A scoped methodology and timeline, sized to the engagement.
03
A first project
Your team follows fielding live on SETHI — moderation, transcripts and synthesis as they land.
04
Repeat, then partner
A second project, then an annual research partnership across your practice.
From the field
Two studies, as they ran.
Inside the NSCLC Testing Paradigm: EU5 Oncologists on Biopsy Dynamics, MET Testing, and a New Product Profile
Hybrid screenshare quantitative25 oncologists · UK, Germany, Spain, Italy, France5 weeks
Oncologists worked through post-TKI testing, biopsy dynamics and the MET testing landscape, and reacted live to a product profile against the options they use today.
Read the full story →NGS Automation and the Future of Sequencing: Lab Directors Across 11 Markets, Conjoint Included
Quantitative + adaptive choice-based conjoint90 lab directors · 11 markets3 weeks
Directors at molecular clinical diagnostic labs on in-house NGS runs, automation and sequencing forecasts, with the conjoint built in-house.
Read the full story →Frequently asked, honestly answered.
How do you work alongside our team?+
As an extension of it. You define the question and own the relationship with your client; we bring verified audiences, fieldwork and analysis at whatever depth the engagement needs.
How fast can you field?+
Feasibility typically comes back within a day; fieldwork launches in days. Two-week sprints are the norm, not the exception.
What if a panel has already let us down on this audience?+
That is usually where we start. Hard-to-reach specialties, rare disease, payers and procurement are recruited by name from a network we own — tell us the audience and we’ll tell you the feasibility.
Will our client ever see who answered?+
No. You and your client know exactly what respondents are — specialty, role, market, screening — never who. Trust rests on methodology and verification, not on exposed identities.
Start with one project.
Tell us the audience and the timeline. Feasibility comes back fast.
Brief us